# Flumazenil for the Treatment of Primary Hypersomnia

> **NCT01183312** · PHASE1,PHASE2 · COMPLETED · sponsor: **Lynn Marie Trotti** · enrollment: 10 (actual)

## Conditions studied

- Hypersomnia
- Primary Hypersomnia
- Idiopathic Hypersomnia
- Narcolepsy Without Cataplexy

## Interventions

- **DRUG:** Flumazenil

## Key facts

- **NCT ID:** NCT01183312
- **Lead sponsor:** Lynn Marie Trotti
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01183312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01183312, "Flumazenil for the Treatment of Primary Hypersomnia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01183312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*